An observational postmarketing safety registry of patients in the UK, Germany, and Switzerland, who have been prescribed Sativex® (THC:CBD, nabiximols) oromucosal spray

Autor: Etges T, Karolia K, Grint T, Taylor A, Lauder H, Daka B, Wright S

Publikováno v: Therapeutics and Clinical Risk Management, Vol Volume 12, Pp 1667-1675 (2016)

Tilden Etges, Kari Karolia, Thomas Grint, Adam Taylor, Heather Lauder, Brian Daka, Stephen Wright GW Pharmaceuticals, Cambridge, UK Abstract: The global exposure of Sativex® (Δ9-tetrahydrocannabinol [THC]:cannabidiol [CBD], nabiximols) is estimated

Externí odkaz: https://doaj.org/article/eeda08b8ffe3424fa5fef39630fbb99a

Fibrinogen - a possible extracellular target for inositol phosphates.

Autor: Grint T; Department of Pharmacy and Pharmacology, University of Bath, Bath BA2 7AY, UK., Riley AM; Wolfson Laboratory of Medicinal Chemistry, Department of Pharmacy and Pharmacology University of Bath, Bath BA2 7AY, UK., Mills SJ; Wolfson Laboratory of Medicinal Chemistry, Department of Pharmacy and Pharmacology University of Bath, Bath BA2 7AY, UK., Potter BV; Wolfson Laboratory of Medicinal Chemistry, Department of Pharmacy and Pharmacology University of Bath, Bath BA2 7AY, UK., Safrany ST; Department of Pharmacy and Pharmacology, University of Bath, Bath BA2 7AY, UK ; Department of Pharmacy, School of Applied Sciences, University of Wolverhampton, Wolverhampton WV1 1LY, UK.

Publikováno v: Messenger (Los Angeles, Calif. : Print) [Messenger (Los Angel)] 2012 Dec 01; Vol. 1 (2), pp. 160-166.